%2016.47.03-1770752981975.webp&w=3840&q=75)
2026 MaTOS GU | Faculty PDF Access
0% Complete
Course Overview
Course Content
Course Details
- Duration
- 0.00 hour
- Released
- Mar 22, 2026
- Last Review
- Mar 22, 2026
- Expires
- Mar 22, 2027
Objectives
Analyze the latest discoveries in genetics and epigenomics in GU cancer, including diagnosis, minimal residual disease (MRD), monitoring for recurrence, and assessment of therapeutic success with targeted therapy and immunotherapy.
Identify the latest drug developments in GU oncology by an expert panel of senior investigators and KOLs in the field.
Distinguish the importance of GU cancer screening and successful implementation, including programs not only based on imaging but also on liquid biopsies and other technologies.
Understand the multidisciplinary application of new developments in GU cancer to the current standards of care.
Evaluate information on new products and developments in GU cancer care for best utilization.
Target Audience
Physicians
Faculty & Disclosure
Faculty
Kerry Schaffer, MD |
E. David Crawford, MD |
Hiba Khan, MD, MPH |
David J. McConkey, PhD |
David M. Albala, MD |
David A. Braun, MD, PhD |
Moshe Ornstein, MD, MA |
Stephanie A. Berg, DO |
Daniel Vaena, MD |
Scott Tagawa, MD |
Yu-Wei Chen, MD, MS |
Nazli Dizman, MD |
Chad Tang, MD |
Amir Iravani, MD |
Arpita Desai, MD |
Yousef Zakharia, MD |
Martin H. Voss, MD |
Jad Chahoud, MD, MPH-MHA |
Karine Tawagi, MD |
Jacek K. Pinski, MD, PhD |
Susan Slovin, MD, PhD |
Amir Iravani, MD |
Atish D. Choudhury, MD, PhD |
Daniel P. Petrylak, MD |
Hikmat Al-Ahmadie, MD |
Rohit K. Jain, MD, MPH |
Burles A. Johnson, III, MD, PhD |
Jason R. Brown, MD, PhD |
Daniel Vaena, MD |
Arlene O. Siefker-Radtke, MD |
Ismaheel O. Lawal, MD, PhD |
Ravi A. Madan, MD |
Hiba Khan, MD, MPH |
Guru Sonpavde, MD |
Nabil Adra, MD, MS |
Disclosure
<p></p>
Accreditation
NA
